Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tegaserod. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 known ✓ | Q13639 | 1/20 | 0.66 |
| ▸ | HTR1A | P08908 | 5/20 | 0.66 |
| ▸ | HTR2C | P28335 | 5/20 | 0.66 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.66 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.66 |
| ▸ | DRD2 | P14416 | 2/20 | 0.66 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.66 |
| ▸ | DRD4 | P21917 | 2/20 | 0.66 |
| ▸ | HTR2A | P28223 | 2/20 | 0.66 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.66 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.66 |
| ▸ | DRD3 | P35462 | 2/20 | 0.66 |
| ▸ | HTR2B | P41595 | 2/20 | 0.66 |
| ▸ | HTR3A | P46098 | 2/20 | 0.66 |
| ▸ | HTR5A | P47898 | 2/20 | 0.66 |
| ▸ | HTR6 | P50406 | 2/20 | 0.66 |
| ▸ | MLNR | O43193 | 1/20 | 0.66 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.66 |
| ▸ | PGR | P06401 | 1/20 | 0.66 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tegaserod SCHEMBL774763 | 0.99 | HTR1A (0.67) | HTR1AHTR2CADRB1ADRB3DRD2 | |
| Tegaserod SCHEMBL16464 | 0.99 | HTR1A (0.67) | HTR1AHTR2CADRB1ADRB3DRD2 | |
| Tegaserod SCHEMBL774764 | 0.99 | HTR1A (0.67) | HTR1AHTR2CADRB1ADRB3DRD2 | |
| Tegaserod SCHEMBL5180106 | 0.98 | HTR1A (0.66) | HTR1AHTR2CADRB1ADRB3DRD2 | |
| Tegaserod SCHEMBL5652626 | 0.98 | HTR1A (0.66) | HTR1AHTR2CADRB1ADRB3DRD2 | |
| Tegaserod SCHEMBL4797289 | 0.98 | HTR1A (0.66) | HTR1AHTR2CADRB1ADRB3DRD2 | |
| Tegaserod SCHEMBL4961312 | 0.98 | HTR1A (0.66) | HTR1AHTR2CADRB1ADRB3DRD2 | |
| Tegaserod SCHEMBL4797293 | 0.98 | HTR1A (0.66) | HTR1AHTR2CADRB1ADRB3DRD2 | |
| Tegaserod SCHEMBL4961318 | 0.98 | HTR1A (0.66) | HTR1AHTR2CADRB1ADRB3DRD2 | |
| Tegaserod SCHEMBL4773941 | 0.98 | HTR1A (0.66) | HTR1AHTR2CADRB1ADRB3DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009141571-A1 | NOVEL POLYMORPH OF TEGASEROD HYDROCHLORIDE | GENERICS [UK] LIMITED (GB) | 2009-11-26 | — | — | WO | claimed |
| CN-109796441-B | Preparation method of impurity A of tipyrimidine hydrochloride | 北京民康百草医药科技有限公司 | 2020-10-16 | — | — | CN | disclosed |
| CN-101990533-A | New salts of tegaserod | GENERICS UK LTD | 2011-03-23 | — | — | CN | disclosed |
| EP-2146958-A1 | PROCESS FOR THE PREPARATION OF FORM A OF TEGASEROD | Generics Ýuk¨Limited (GB) | 2010-01-27 | — | — | EP | disclosed |
| WO-2009141571-A1 | NOVEL POLYMORPH OF TEGASEROD HYDROCHLORIDE | GENERICS [UK] LIMITED (GB) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009141571-A1 | NOVEL POLYMORPH OF TEGASEROD HYDROCHLORIDE | GENERICS [UK] LIMITED (GB) | 2009-11-26 | — | — | WO | disclosed |
| WO-2008142445-A1 | PROCESS FOR THE PREPARATION OF FORM A OF TEGASEROD | GENERICS [UK] LIMITED (GB) | 2008-11-27 | — | — | WO | disclosed |
| EP-1740539-A2 | PREPARATION OF TEGASEROD AND TEGASEROD MALEATE | Teva Pharmaceutical Industries Ltd (IL) | 2007-01-10 | — | — | EP | disclosed |
| WO-2006116953-A1 | A METHOD FOR THE PREPARATION OF TEGASEROD AND SLECTED SALTS THEREOF | ZENTIVA, A.S. (CZ) | 2006-11-09 | — | — | WO | disclosed |
| US-20060106086-A1 | Preparation of tegaserod and tegaserod maleate | TEVA PHARMACEUTICALS USA, INC. | 2006-05-18 | — | — | US | disclosed |
| WO-2005105740-A2 | PREPARATION OF TEGASEROD AND TEGASEROD MALEATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106086-A1 | Preparation of tegaserod and tegaserod maleate | MLNR, SLC10A2, MLN | HTR4 418/4885HTR1A 229/4885HTR2C 1232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.